Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Optimer Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-11-25 15:28:03 -

www.optimerpharma.com - Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference at The New York Palace in New York City on December 2, 2008, 12:00 p.m. Eastern Time.
A live audio webcast of this presentation will be accessible on the Company"s website at

href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.optimerpharma.com&esheet=5839471&lan=en_US&anchor=www.optimerpharma.com&index=1" title="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.optimerpharma.com&esheet=5839471&lan=en_US&anchor=www.optimerpharma.com&index=1" rel="nofollow" target="_blank">cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .., under the investors section. A replay of this presentation will be available at the same location for thirty days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. OPT-80 is the only antibiotic therapy currently under Phase 3 worldwide development for Clostridium difficile infection. Prulifloxacin is an antibiotic being developed for the treatment of travelers" diarrhea, a form of infectious diarrhea. Additional information can be found at http://http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.optimerpharma.com&esheet=5839471&lan=en_US&anchor=www.optimerpharma.com&index=2.


Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

or

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005


Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com